Search
Clinician Ordering Portal
Scientific evidence
Risk stratification of patients with stage I cutaneous melanoma using 31-gene expression profiling
Jan 2021
Examined the prognostic value of the 31-gene expression profile (31-GEP) test for the risk of recurrence in stage I CM patients according to 31-GEP class.
Publication: Journal of Clinical and Aesthetic Dermatology
A dermatologist’s guide to implementation of gene expression profiling in the management of melanoma
Nov 2020
Expert panel of 5 leading dermatologists with 31-GEP experience convened to review literature and create a shared decision-making model/algorithm.
Publication: Journal of Clinical and Aesthetic Dermatology
Independent validation of a tissue systems pathology assay to predict future progression in non-dysplastic Barrett’s esophagus: a spatial-temporal analysis
Oct 2020
Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.
Publication: Clinical and Translational Gastroenterology
Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations
Oct 2020
Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice.
Publication: Future Oncology
Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication
Aug 2020
Purpose: To systematically evaluate and compare the effects of using small-gauge needles and vitrectors on the ability to obtain adequate diagnostic and prognostic uveal melanoma biopsy specimens.
Publication: American Journal of Ophthalmology
Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma
Aug 2020
Retrospective review and early experience in utilizing 31-GEP in intermediate melanomas and its effect on clinical management.
Publication: The American Surgeon
Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis
Jul 2020
The prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) predicts metastatic risk based on primary tumor biology. Here we report outcomes from a prospective registry of 15-GEP-tested patients, and a meta-analysis with published cohorts.
Publication: Ocul Oncol Pathol
Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus
Jun 2020
A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.
Publication: American Journal of Gastroenterology
Clinical validity of a gene expression signature in diagnostically uncertain neoplasms
Jun 2020
A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.
Publication: Personalized Medicine
Gene expression profiling prognostication of posterior uveal melanoma
Jun 2020
Investigate the influence of tumor size by American Joint Committee on Cancer (AJCC) stage, Collaborative Ocular Melanoma Study (COMS) size, tumor largest basal diameter (LBD), and tumor thickness on prognostication by gene expression profiling (GEP) class.
Publication: Ophthalmology Retina
A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis
May 2020
Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.
Publication: SKIN: Journal of Cutaneous Melanoma
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual